pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$RAREUltragenyx Pharmaceutical Inc.

$RARE17.58+5.27%
Novato, CA, USupdated 8h ago

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
9
marketed
3
phase 3
4
catalysts ytd
5
approvals ytd
0
recalls ytd
0

Pipeline(9)

pipeline depth9 products
Phase 3: 4Marketed: 3pre_registration: 2
4Phase 33Marketed2pre_registration
Marketed
burosumab
X-Linked Hypophosphatemic Rickets
Marketed
triheptanoin
Fatty Acid Biosynthesis Disorders
Marketed
vestronidase alfa
Mucopolysaccharidosis VII (MPS VII) (Sly Syndrome )
Phase 3
apazunersen sodium
Angelman Syndrome
Phase 3
avalotcagene ontaparvovec
Ornithine-Transcarbamylase Deficiency
Phase 3
rivunatpagene miziparvovec
Wilson Disease
Phase 3
setrusumab
Osteogenesis Imperfecta
Sclerostin
pre_registration
pariglasgene brecaparvovec
Glycogen Storage Disease 1A
pre_registration
rebisufligene etisparvovec
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome )

📅 Upcoming

Jan 15, 2027
pdufa
$RARE17.58+5.27%
in 2mo
Rare Disease PDUFA 2027-01-15
Rare Disease
→
Jan 21, 2027
pdufa
$RARE17.58+5.27%
in 2mo
Ultragenyx Pharmaceutical Inc. PDUFA 2027-01-21
Ultragenyx Pharmaceutical Inc.
→
Jan 21, 2027
pdufa
$RARE17.58+5.27%
in 2mo
Ultragenyx Pharmaceutical Inc. PDUFA 2027-01-21
Ultragenyx Pharmaceutical Inc.
→
Feb 1, 2027
pdufa
$RARE17.58+5.27%
in 2mo
mitapivat sulfate PDUFA 2027-02-01
mitapivat sulfate
→

🕒 Recent(90d)

earnings (1)
Nov 3, 2026
earnings
$RARE17.58+5.27%
16d ago
Ultragenyx Pharmaceutical Inc. earnings
Ultragenyx Pharmaceutical Inc.
→
view all catalysts →

Active trials

  • —Tumor-induced Osteomalacia Disease Monitoring Programactive not recruitingn=23
  • phase2A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)terminatedn=55
  • phase3Setrusumab vs Placebo for Osteogenesis Imperfectaactive not recruitingn=183
  • phase3Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfectaactive not recruitingn=69
  • —Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Programrecruitingn=140
  • phase3A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAODactive not recruitingn=69
  • phase3Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSHrecruitingn=36
  • phase3Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)active not recruitingn=129
🐶 Hiring Signal
13 open roles at Ultragenyx Pharmaceutical Inc. →

Where Ultragenyx Pharmaceutical Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaRare Disease 13
departmentManufacturing / CMC 8Commercial 2Medical Affairs 1Supply Chain 1

News

  • FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease
    FDA today approved Infilbray (venglustat) tablets, the first treatment for the neurological symptoms of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg (approx…
    fda_press · 10h ago
  • White House pulls nomination for FDA nominee Overton
    The sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say.
    biopharma_dive · 12h ago
  • CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s
    Biogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito Therapeutics missed the mark—though the latter plans to file for FDA approva…
    biospace · 13h ago
  • Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns
    Merck is canning multiple Phase 3 studies of nemtabrutinib after a benefit-risk review derailed hopes of the asset entering the non-covalent BTK inhibitor race.
    biospace · 14h ago
  • Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
    The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech hist…
    biospace · 18h ago
  • 5 acquisitions that forced Big Pharmas to co-parent
    Acquiring a biotech with an existing Big Pharma partner can impose financial and strategic constraints around data sharing and milestone and royalty payments—but it is “rarely a deal-breaker,” acco…
    biospace · 23h ago
  • White House yanks Overton nomination hours before committee vote
    The Trump administration withdrew the nomination of Heidi Overton for FDA commissioner Tuesday evening, reportedly due to opposition from Republican Senators.
    biospace · 1d ago
  • Larbi Inc. Recalls Yellow Dock Root Because of Possible Health Risk
    Larbi Inc. of Valley Cottage, NY, is recalling three lots of Herb To Body Yellow Dock Root C/S 4oz, because it has the potential to be contaminated with Salmonella, an organism which can cause seri…
    fda_recalls · 1d ago
  • Beren wins FDA approval for long-studied rare disease drug
    A molecule designed by government scientists more than a decade ago has won FDA approval to treat infantile-onset Niemann-Pick disease type C, capping a winding and rocky development path. Beren Th…
    endpoints · 1d ago
  • FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer
    FDA approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer.
    fda_press · 1d ago
view all news mentions →
identifiers
ticker
$RARE
SEC CIK
0001515673
country
US
source
sec_tickers
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 7m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?